Intelligence · Clinical Development
Pipeline search results
Programs matching “alzheimer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 141 pipeline programs matching "alzheimer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Active Treatment- CT1812 100 mg
COGNITION THERAPEUTICS INC
Alzheimer Disease
1 trial -
Azeliragon
vTv Therapeutics
Alzheimer Disease
1 trial -
BP42155
Hoffmann-La Roche
Alzheimer's disease
1 trial -
BP44745
Hoffmann-La Roche
Alzheimer’s Disease
1 trial -
CERE-110: Adeno-Associated Virus injection Surgery
SANGAMO THERAPEUTICS, INC
Alzheimer's Disease
1 trial -
CN008-0003
Bristol-Myers Squibb Australia Pty Ltd
Early Alzheimer’s Disease
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Alzheimer's Disease
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Alzheimer Disease
3 trials -
CT1812
COGNITION THERAPEUTICS INC
Mild to Moderate Alzheimer's Disease
1 trial -
CT1812
COGNITION THERAPEUTICS INC
Early Alzheimer's Disease
1 trial -
CVHB937A12201
Novartis Pharmaceuticals
Alzheimer’s disease
1 trial -
D20-P012
Pari Pharma GmbH
Alzheimer Disease
1 trial -
Dexmedetomidine
COGNITION THERAPEUTICS INC
Alzheimer Disease
1 trial -
ExPlas
Wuhan Createrna Science and Technology Co., Ltd
Early symptomatic phase Alzheimer's disease
1 trial -
Flortaucipir, Placebo to match LY3372689
Eli Lilly Co.
Alzheimer Disease
1 trial -
GSK4527226
GlaxoSmithKline
Alzheimer's Disease
1 trial -
I5T-MC-AACI
Eli Lilly Co.
Alzheimer Disease
1 trial -
LX1001
BRIGHT MINDS BIOSCIENCES INC.
Alzheimer Disease
1 trial -
Lamivudina Aurovitas 300 mg comprimidos recubiertos con película EFG
MEDA Pharma GmbH & Co. KG
Mild Cognitive impairment due to Alzheimer Disease
1 trial -
Leuprolide acetate
Voyager Therapeutics
Alzheimer Disease
2 trials -
MK-1167
Merck KGaA, Darmstadt, Germany
Alzheimer Disease
1 trial -
MK-1167-008
Merck Sharp and Dohme
Alzheimer’s disease dementia
1 trial -
MK-2214
Merck KGaA, Darmstadt, Germany
Early Alzheimer's Disease
1 trial -
MK-2214-004
Merck Sharp and Dohme
Alzheimer’s Disease
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.